Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

Owen O'Connor, MD, PhD
Published: Wednesday, Jan 03, 2018



Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 
SELECTED
LANGUAGE


Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x